Janux Therapeutics (JANX) EBT (2020 - 2026)

Janux Therapeutics (JANX) has reported EBT for 7 consecutive years, with -$52.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 65.83% year-over-year to -$52.9 million; the TTM figure through Mar 2026 stood at -$348.5 million (up 56.94% YoY), while the FY2025 annual figure was -$143.2 million, up 66.74% from the prior year.
• EBT retreated to -$52.9 million in Q1 2026 per JANX's latest filing, from -$31.9 million in the prior quarter.
• Across five years, EBT topped out at -$11.8 million in Q4 2023 and bottomed at -$341.5 million in Q3 2024.
• Historically, EBT has averaged -$102.8 million across 5 years, with a median of -$54.4 million in 2022.
• Annual changes were most pronounced in 2022 — EBT plunged 2020.58% — and 2026, when it soared 65.83%.
• Janux Therapeutics' EBT stood at -$16.4 million in 2022, then climbed by 28.34% to -$11.8 million in 2023, then plunged by 71.93% to -$20.2 million in 2024, then plunged by 58.02% to -$31.9 million in 2025, then slumped by 65.47% to -$52.9 million in 2026.
• Business Quant data shows JANX's EBT at -$52.9 million in Q1 2026, -$31.9 million in Q4 2025, and -$131.2 million in Q3 2025.